Northwest Biotherapeutics

Development-stage American pharmaceutical company

NWBO OTC Markets Group SEC CIK 1072379 LEI 5493002DRWWEOWTT8005
Follow Northwest Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $883K +341.5% vs same quarter last year
Net income −$28.8M −7.2% vs same quarter last year
EPS, diluted −$0.02 +0% vs same quarter last year
Operating cash flow −$8.8M +37% vs same quarter last year
Revenue by quarter
$231K
$375K
$131K
$200K
$672K
$494K
$807K
$883K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.4M−$60.2M
FY24$1.4M−$83.8M
FY23$1.9M−$62.6M
FY22$1.7M−$105M
FY21$1M-
FY20$1.3M−$529.8M
FY19$2.4M−$20.8M
FY18$412K−$35.8M
FY17$336K−$73.1M
FY16$623K−$80.2M
FY15$1.7M−$114.7M
FY14$1.5M−$135.6M
FY13$809K−$65.8M
FY12$772K−$67.3M
FY11$10K−$32.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400000%−300000%−200000%−100000%0%100000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−4347.9%−4365.9%
FY24-−4812.4%−6062.1%
FY23-−2873.1%−3240.1%
FY22-−3991.7%−6240.8%
FY21-−5244%-
FY20-−6708.4%−41039.6%
FY19-−1161%−863.6%
FY18-−10068.2%−8687.9%
FY17-−16273.2%−21768.8%
FY16-−12723.3%−12875.4%
FY15-−7261.9%−6598.1%
FY14-−6956.2%−9328.3%
FY13100%−6857.1%−8132.1%
FY12100%−5676.8%−8720.2%
FY11100%−267870%−328300%
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$46.3M
FY24−$58M
FY23-
FY22-
FY21-
FY20-
FY19−$32M
FY18-
FY17-
FY16-
FY15-
FY14-
FY13−$37.8M
FY12−$22.8M
FY11−$14.8M
Returned to shareholdersDividends paid and shares bought back
$0$100K$200K$300KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15$0
FY14$0
FY13$240K
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Northwest Biotherapeutics
  • Healthcare median
−400000%−300000%−200000%−100000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNorthwest BiotherapeuticsHealthcare median
FY25−4365.9%−30.6%
FY24−6062.1%−47%
FY23−3240.1%−58%
FY22−6240.8%−80.4%
FY21-−71.9%
FY20−41039.6%−62.2%
FY19−863.6%−46.3%
FY18−8687.9%−49.6%
FY17−21768.8%−45.9%
FY16−12875.4%−36%
FY15−6598.1%−38.4%
FY14−9328.3%−35.5%
FY13−8132.1%−37.1%
FY12−8720.2%−29.1%
FY11−328300%−27.9%